POTENTIALS FOR THE USE OF AMBROXOL IN VARIOUS RESPIRATORY DISEASES


Citar

Texto integral

Acesso aberto Acesso aberto
Acesso é fechado Acesso está concedido
Acesso é fechado Acesso é pago ou somente para assinantes

Resumo

This article is dedicated to the analysis of the results of clinical studies on the efficacy and safety of ambroxol hydrochloride. Classification and mechanism of action of mucolytics are considered in details. Current evidence on the effectiveness of ambroxol against bacterial films is analyzed that attaches special importance in the present conditions of antibiotic resistance. A comparative evaluation of pharmacokinetic and pharmacodynamic characteristics of the drug compared with bromhexine is performed. It is emphasized that ambroxol has higher bioavailability as compared with bromhexine, allowing to regard this drug as the most effective in this pharmacotherapeutic group.

Texto integral

Acesso é fechado

Sobre autores

Yu. Gorinova

FSAI “Scientific Center for Children's Health" of RMPH

N. Burkina

FSAI “Scientific Center for Children's Health" of RMPH

O. Simonova

FSAI “Scientific Center for Children's Health" of RMPH

Email: oisimonova@mail.ru
MD, Head of the Department of Pulmonology and Allergology

Bibliografia

  1. Stetinova V., Herout V., Kvetina J. In vitro and in vivo antioxidant activity of ambroxol. Clin. Exp. Med. 2004;(4):152-58.
  2. Beeh K.M., Beier J., Esperester A., Paul L.D., Antiinflammatory properties of ambroxol, Eur. J. Med. Res. 2008;(13):557-62.
  3. Gaida W., Klinder K., Arndt K., Weiser T. Ambroxol, a Nav1.8-preferring Na (+) channel blocker, effectively suppresses pain symptoms in animal models of chronic, neuropathic and inflammatory pain. Neuropharmacology. 2005;(49):1220-27.
  4. Leffler A., Reckzeh J., Nau C. Block of sensory neuronal Na+ channels by the secreolytic ambroxol is associated with an interaction with local anesthetic binding sites. Eur. J. Pharmacol. 2010;(630):19-28.
  5. Yang B., Yao D.F., Ohuchi M., Ide M., Yano M., Okumura Y., Kido H. Ambroxol suppresses influenza-virus proliferation in the mouse airway by increasing antiviral factor levels, Eur. Respir. J. 2002;(19):952-58.
  6. Malerba M., Ragnoli B. Ambroxol in the 21 st century: pharmacological and clinical update, Expert Opin. Drug Metab. Toxicol. 2008;(4):1119-29.
  7. Boehringer Ingelheim Ltd Consumer Healthcare, Summary of Product Characteristics last updated on medicines.ie: 31/07/2014, Lysopadol Mint 20 mg Lozenges. http://www.medicines.ie/ printfriendlydocument.aspx?documentid= 1516 7&companyid=2470
  8. Weiser T. Comparison of the effects of four Na+ channel analgesics on TTX-resistant Na+ currents in rat sensory neurons and recombinant Nav1.2 channels, Neurosci. Lett. 2006;(395): 179-84.
  9. Gibbs B.F., Schmutzler W., Vollrath I.B., Brosthardt P., Braam U., Wolff H.H., Zwadlo G. Klarwasser, Ambroxol inhibits the release of histamine, leukotrienes and cytokines from human leukocytes and mast cells, Inflamm. Res. 1999;(48):86-93.
  10. De Mey C., Peil H., Kölsch S., Bubeck J., Vix J. Efficacy and safety of ambroxol Lozenges in the treatment of acute uncomplicated sore throat, Arzneimittel-Forsch. 2008;(58):557-68.
  11. Fraschini F., Scaglione F., Scarpazza G., Marchi F., Calzavara M. Effects of a mucolytic agent on the bioavailability of antibiotics in patients with chronic respiratory diseases, Curr. Ther. Res. 1988;(43):734-42.
  12. Hoiby N., Ciofu O., Johansen H.K., Song Z.J., Moser C., Jensen P.O., et al. The clinical impact of bacterial biofilms. Int J Oral Sci 2011; 3:55-65.
  13. O'Toole G., Kaplan H.B., Kolter R. Biofilm formation as microbial development. Annu Rev Microbiol 2000;54:49-79.
  14. Li Y.H., Tian X. Quorum sensing and bacterial social interactions in biofilms. Sensors (Basel) 2012;12:2519-38.
  15. Bhardwaj A.K., Vinothkumar K., Rajpara N. Bacterial quorum sensing inhibitors: attractive alternatives for control of infectious pathogens showing multiple drug resistance. Recent Pat Antiinfect Drug Discov. 2013; 8:68-83.
  16. Zhang Y., Fu Y., Yu J., Ai Q., Li J., Peng N. Synergy of ambroxol with vancomycin in elimination of catheter-related Staphylococcus epi-dermidis biofilm in vitro and in vivo. J Infect Chemother. 2015;21(11):808-15.
  17. Li F., Yu J., Yang H., Wan Z., Bai D. Effects of ambroxol on alginate of mature Pseudomonas aeruginosa biofilms. Curr Microbiol 2008; 57:1-7.
  18. Pulcrano G., Panellis D., De Domenico G., Rossano F., Catania M.R. Ambroxol influences voriconazole resistance of Candida parapsilosis biofilm. FEMS Yeast Res. 2012; 12:430-38.
  19. Tyrakowski T., Greczko I., Sedlaczek A., Banach B., Bartlomwicz M., Wojciechowska M., et al. Electrophysiological investigation of the effects of ambroxol on the transepithelial Na+ ion transport pathway in airways. Pol. J. Pharmacol. 1998;50:31-8.
  20. Li Q., Yao G., Zhu X. High-dose ambroxol reduces pulmonary complications in patients with acute cervical spinal cord injury after surgery. Neurocrit Care. 2012;16:267-72.
  21. Ulas M.M., Hizarci M., Kunt A., Ergun K., Kocabeyoglu S.S., Korkmaz K., et al. Protective effect of ambroxol on pulmonary function after cardiopulmonary bypass. J. Cardiovasc. Pharmacol. 2008;52:518-23.
  22. Refai M., Brunelli A., Xiume F., Salati M., Sciarra V., Socci L., et al. Short-term perioperative treatment with ambroxol reduces pulmonary complications and hospital costs after pulmonary lobectomy: a randomized trial. Eur. J. Cardiothorac. Surg. 2009;35: 469-73.
  23. Nash E.F., Stephenson A., Ratjen F., Tullis E. Nebulized and oral thiol derivatives for pulmonary disease in cystic fibrosis. Cochrane Database Syst. Rev. 2009;1:CD007168.
  24. Poole P, Black PN, Cates CJ. Mucolytic agents for chronic bronchitis or chronic obstructive pulmonary disease. Cochrane Database Syst. Rev. 2012;8:CD001287.
  25. Бронхиты у детей. Пособие для врачей / Под ред. В.К. Таточенко. М., 2004. 89 с.
  26. Овчаренко С.И. Муколитические (муко регуляторные) препараты в лечении хронической обструктивной болезни легких. РМЖ. 2002;10(4).
  27. Амелина Е.Л., Анаев Э.Х., Красовский С.А., Романова Л.К., Симонова О.И., Черняев А.Л., Чикина С.Ю. Мукоактивная терапия / Под ред. А.Г. Чучалина, А.С. Белевского М., 2006. 128 с.
  28. Симонова О.И., Горинова Ю.В. Ингаляционная терапия раствором амброксола (Лазолвана®): преимущества, особенности применения, эффективность. РМЖ. Педиатрия. 2014;6:1530-34.
  29. Симонова О.И. Клинические эффекты амброксола гидрохлорида (лазолвана®): от чего зависит эффективность препарата? Педиатрия. 2011;5:128-33.
  30. Wauer R.R., et al. Randomised double blind trial of ambroxol for the treatment of respiratory distress syndrome. Eur J. Paediatr. 1992; 151:357-63.
  31. Weinmann H.-M. Ambroxol in paediatrics. Therapiewoche. 1981:31:7940-47.
  32. Bonnetti P. Ambroxol plus amoxicillin versus amoxicillin alone in various respiratory tract infections. Investig. Medica Internacional. 1993;20:99-103.
  33. Spatola J., et al. Influence of ambroxol on lung tissue penetration of amoxicillin. Arzneim.-Forsch. Drug Res. 1987;37(11):965-66.
  34. Fraschini F. Effects of mucolytic agent on the bioavailability of antibiotics in patients with chronic respiratory diseases. Current Ther. Res. 1988;43(4):734-42.

Arquivos suplementares

Arquivos suplementares
Ação
1. JATS XML
Baixar

Este site utiliza cookies

Ao continuar usando nosso site, você concorda com o procedimento de cookies que mantêm o site funcionando normalmente.

Informação sobre cookies